Figure 6.

A small molecule inhibitor of TBK1 inhibits lung tumorigenesis and promotes antitumor T cell responses. a-c, Schematic of experimental design (a), a representative image of H&E staining of lung tissue (b, scale bar, 100 μm), and summary graphs of lung weights, tumor numbers, and average tumor size (c) of Kras^LA2 mice treated with the TBK1 inhibitor amlaxanox (Am, 25 mg/kg body weight), anti-CTLA4, amlexanox + anti-CTLA4, or vehicle (DMSO) and IgG isotype controls (n=8 per genotype). d-g, Tumor growth curves (d), summary of day 22 tumor mass (e), and flow cytometric analysis of IFNγ- and granzyme B (GzmB)-producing tumor-infiltrating CD4 and CD8 T cells presented as representative plots (f) and summary graphs (g) of LLC-injected wildtype B6 mice treated with anti-CTLA4 or an IgG isotype control (i.p., on day 3, 6, and 9), amlexanox or DMSO solvent control (at tumor site or intratumorally, from day 1 to 22). n = 7 mice per group. h, Immunoblot analysis of the indicated phosphorylated (p-) or total proteins in whole-cell lysates of tumor cells (CD45^–) or tumor-infiltrating immune cells (CD45⁺) isolated from day 22 tumor of the LLC-implanted mice treated with as indicated. Data are representative of three independent experiments, and bar graphs are presented as mean±s.d. Two-sided unpaired Student’s t-test (c), One-way ANOVA with Bonferroni correction (e,g), Two-way ANOVA with Bonferroni correction (d). Source data for graphs are provided in Statistical Source Data Fig. 6 and unprocessed blots are shown in Unprocessed Blots Fig. 6.